CSIMarket Company Name, Ticker, Suppliers, else..
 
Liquidia Corporation  (NASDAQ: LQDA)
 
Price: $67.6800 $-0.98 -1.427%
Day's High: $69.20999908447266 Week Perf: 1.15 %
Day's Low: $ 67.07 30 Day Perf: -24.98 %
Volume (M): 1,328,362 52 Wk High: $ 93.61
Volume (M$): $ 0 52 Wk Avg: $46.12
Open: $68.00 52 Wk Low: $21.15



 Market Capitalization (Millions $) 6,863
 Shares Outstanding (Millions) 101
 Employees 216
 Revenues (TTM) (Millions $) 451
 Net Income (TTM) (Millions $) 139
 Cash Flow (TTM) (Millions $) 49
 Capital Exp. (TTM) (Millions $) 17

Business Description


Liquidia Corporation is a pharmaceutical company that specializes in the development of therapeutics using its unique particle engineering technology. The company's proprietary PRINT technology allows for the precise engineering of particles to create drug candidates with improved performance and delivery. Liquidia focuses on developing both in-house and partnered therapeutics for various diseases, including respiratory diseases, cancer, and other conditions with significant unmet medical needs. The company aims to leverage its particle engineering capabilities to improve drug efficacy, safety, and patient outcomes.


   Company Address: 419 Davis Drive, Suite 100 Morrisville 27560 NC
   Company Phone Number: 328-4400   Stock Exchange / Ticker: NASDAQ LQDA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
HOTH   -11.96%    
MIRM        1.51% 
TBPH        0.12% 
XERS        0.47% 
ATR   -5.53%    
• View Complete Report
   



Product Service News

Liquidia Corporation’s YUTREPIA (Treprostinil) Inhalation Powder Receives FDA Acceptance for New Drug Application R...

Published Fri, Mar 28 2025 2:02 PM UTC

Liquidia Corporation has recently announced a significant milestone in its journey to bring YUTREPIA (treprostinil) inhalation powder to market. The U.S. Food and Drug Administration (FDA) has officially accepted the company s resubmission of its New Drug Application (NDA) for this innovative treatment. This development marks a crucial step in the potential commercialization...
Clinical Study

Liquidia and Pharmosa Biopharm Collaborate to Innovate PAH Treatment with Sustained Release Treprostinil,

Published Wed, Oct 2 2024 10:00 AM UTC

Advancements in Inhaled Therapies: Liquidia and Pharmosa Biopharm Strengthen Collaboration on Sustained Release Treprostinil Innovative pharmaceutical solutions continue to evolve as global health challenges demand more effective and sustained treatments. In an effort to address the pressing needs in pulmonary arterial hypertension (PAH) management, Liquidia Corporation and ...
Clinical Study

Clearing the Path: Legal and Regulatory Advances Raise Hopes for YUTREPIA's FDA Approval

Published Mon, Apr 1 2024 10:01 AM UTC

In a recent breakthrough for Liquidia Corporation, the U.S. District Court for the District of Delaware has set aside an injunction that had previously prevented the U.S. Food and Drug Administration (FDA) from issuing final approval of Liquidia s New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder. This development signifies significant progress and ope...
Product Service News

Liquidia Corporation Responds to United Therapeutics Lawsuit, Asserts Counterclaims and Highlights Patent Office Oversight Failure

Published Mon, Jan 8 2024 1:23 PM UTC

In a recent development in the pharmaceutical industry, Liquidia Corporation (NASDAQ: LQDA) has filed its response and counterclaims against United Therapeutics Corporation (UTHR). This legal battle revolves around alleged patent infringement regarding Liquidia s New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder. The filing also sheds light on several ...
Clinical Study

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Published Fri, Jan 5 2024 11:45 AM UTC

Liquidia Corporation, a leading pharmaceutical company, recently shared an update on the development of its extensive clinical pipeline programs aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension connected with interstitial lung disease (PH-ILD).The company s most promising investigational drugs, YUTREPIA (treprostinil) inhalation powder and L...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 48.69
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 15.22
Price to Sales (Expected) -
Price to Book 35.17
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.5
Working Capital Ratio 2.31
Leverage Ratio (MRQ) 1.67
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 1.39 $
Revenues (TTM) 4.45 $
Cash Flow (TTM) 0.49 $
Cash 2.8 $
Book Value 1.92 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 2,087,532
Net Income per Employee (TTM) 641,694
Receivable Turnover Ratio (TTM) 6.61
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 1.19

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 49.81 %
Net Margin (MRQ) 43.52 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 7.29 %

Management Effectiveness Current
Return On Assets (TTM) 36.48 %
Return On Investment (TTM) 42.09 %
Return On Equity (TTM) 149.64 %
Dividend Yield -
Pay out Ratio (TTM) -



Liquidia's Segments
Product    174.9 % of total Revenue
Service    2.49 % of total Revenue
Single reportable segment    177.39 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.